Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Novartis Sues Lupin, Torrent Over Blood-Pressure Medicine

May 14 (Bloomberg) -- Novartis AG sued Lupin Ltd. and Torrent Pharmaceuticals Ltd. for infringing patents on its Exforge HCT blood-pressure medicine.

Lupin, based in Mumbai, and Torrent, based in Ahmedabad, India, are seeking to make generic versions of the drug before the expiration of two patents. Novartis requested a court order barring the companies from making, using or offering for sale copies of the drugs until the patents have expired, according to complaints filed today in federal court in Wilmington, Delaware.

Novartis, based in Basel, Switzerland, is counting on new products, including Exforge, to help replace revenue lost when the company’s best sellers, Diovan for hypertension and Gleevac for leukemia, start to lose U.S. patent protection later this year and in 2015, respectively. The two Exforge patents in dispute expire in 2017 and 2023, according to U.S. Food and Drug Administration records.

Dawn Chitty, vice president of regulatory affairs at Torrent’s U.S. offices in Kalamazoo, Michigan, said the company doesn’t comment on pending litigation. Edith St-Hilaire, a spokeswoman for Lupin, didn’t immediately return phone and e-mail messages seeking comment on the lawsuit.

The cases are Novartis Pharmaceuticals Corp. v. Lupin Ltd, 12-00595; Novartis Pharmaceuticals Corp. v. Torrent Pharmaceuticals, 12-00596, U.S. District Court, District of Delaware (Wilmington).

To contact the reporters on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net; Sophia Pearson in Wilmington at spearson3@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.